+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Asia Pacific Antacids Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Dosage Form; Drug Class; Distribution Channel

  • PDF Icon

    Report

  • 150 Pages
  • April 2021
  • Region: Asia Pacific
  • The Insight Partners
  • ID: 5316789
UP TO OFF until Mar 31st 2024
The Asia Pacific antacids market is expected to reach US$ 3,255.05 million in 2027 from US$ 2,287.19 million in 2019. The market is estimated to grow at a CAGR of 4.6% during 2020-2027.

The growth of the Asia Pacific antacids market is attributed to the key driving factors such as the increasing launches of innovative products by market players and the rising incidence of obese population. However, the stringent regulatory norms and several challenges associated with gastrointestinal diseases hinder the market growth.

Many players operating in the Asia Pacific antacid market are developing and launching new products. The companies adopt strategies such as new products’ launches to expand their geographic presence and capacity to cater to many customers. For instance, in October 2020, Dr. Reddy's Laboratories (an Indian multinational pharmaceutical) launched an over-the-counter (OTC) generic drug - Famotidine tablets - to treat gastroesophageal reflux disease in the market.

Similarly, in May 2017, the consumer products division of Piramal Enterprises, headquartered in Mumbai, India, launched the paan-flavored (betel leaf flavor) variant of its antacid brand, Polycrol. With the pleasant taste, Polycrol offers quick relief from acidity. Furthermore, one of India's leading drug makers, Sun Pharmaceuticals Ltd launched Pepmelt (a mouth-melt granules format) in February 2016. This product is the company’s first consumer healthcare product. Additionally, in May 2017, GSK Consumer Healthcare (a leading global consumer healthcare company) launched “ENO Cooling” - driven by Fast Cooling Technology. The product quickly relieves from acidity and offers an instant cooling sensation. Therefore, the increasing launches of innovative products associated with antacids drive the growth of the Asia Pacific antacid market.

Countries in the Asia Pacific are facing challenges due to the rapidly increasing number of COVID-19 confirmed cases. The countries in the region expect the second wave of the outbreak due to the large-scale movements of people within the countries and internal travel. As a precautionary measure, the governments are imposing restrictions on human movements. The governments have preferred to continue to permit business operations and economic activities. Thus, the supply of the consumer health products such as antacids is less affected. For instance, India is among the largest hubs for pharmaceutical manufacturing. The country contributes to the majority shares of supplying generic and branded drugs across the world. The manufacturers are operating with full capacity. Thus, it is expected to maintain the gap between the demand and supply of the products in the associated markets. The outbreak has severely affected the tourism industry and imposed supply chain disruptions. Moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent transmission of the coronavirus that causes COVID-19.

Acidity is among the common side effects associated with the medications prescribed for COVID-19 and other chronic diseases. Thus, the demand for antacids is rising during the ongoing COVID-19 outbreak.

Based on dosage form, the Asia Pacific antacids market is segmented into tablet, liquid, and others. The tablet segment held the largest market share in 2019, whereas the liquid segment is anticipated to register the highest CAGR in the market during the forecast period.

The Asia Pacific antacids market, based on drug class, is segmented into proton pump inhibitors, H2 antagonist, and acid neutralizers. The proton pump inhibitors segment held the largest market share in 2019. Also, the same segment is anticipated to register the highest CAGR in the market during 2020-2027.

By distribution channel, the Asia Pacific antacids market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment held the largest market share in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period.

A few of the primary and secondary sources referred to while preparing the report on the Asia Pacific antacids market are National Center for Health Statistics (NCHS), the India Brand Equity Foundation (IBEF), and the Australian Self Medication Industry (ASMI).

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Antacid Market - By Dosage Form
1.3.2 Antacid Market - By Drug Class
1.3.3 Antacid Market - By Distribution Channel
1.3.4 Asia Pacific Antacid Market - By Country
2. Asia Pacific Antacid Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Antacid Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Antacid Market- Asia Pacific PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Antacid Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Innovative Product Launches by Market Players
5.1.2 Higher Incidence of the Obese Population
5.2 Market Restraints
5.2.1 Stringent Regulatory Norms and Several Challenges Associated with Gastrointestinal Diseases
5.3 Market Opportunities
5.3.1 Increasing Demand for OTC (Over the Counter) Antacid Medications
5.4 Future Trends
5.4.1 Rising Development of the Pharmaceutical Industry
5.5 Impact Analysis
6. Antacid Market - Asia Pacific Analysis
6.1 Asia Pacific Antacid Market Revenue Forecasts and Analysis
7. Asia Pacific Antacid Market Analysis and Forecasts to 2027 - By Dosage Form
7.1 Overview
7.2 Antacid Market Revenue Share, by Dosage Form (2019 and 2027)
7.3 Tablet
7.3.1 Overview
7.3.2 Tablet: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Liquid
7.4.1 Overview
7.4.2 Liquid: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8. Asia Pacific Antacid Market Analysis and Forecasts to 2027- By Drug Class
8.1 Overview
8.2 Antacid Market Revenue Share, by Drug Class (2019 and 2027)
8.3 Proton Pump Inhibitors
8.3.1 Overview
8.3.2 Proton Pump Inhibitors: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8.4 H? Antagonist
8.4.1 Overview
8.4.2 H? Antagonist: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Acid Neutralizers
8.5.1 Overview
8.5.2 Acid Neutralizers: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8.5.3 Magaldrate
8.5.3.1 Overview
8.5.3.2 Magaldrate: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8.5.4 Sucralfate
8.5.4.1 Overview
8.5.4.2 Sucralfate: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
8.5.5 Others
8.5.5.1 Overview
8.5.5.2 Others: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
9. Asia Pacific Antacid Market Analysis and Forecasts to 2027- By Distribution Channel
9.1 Overview
9.2 Antacid Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Online Pharmacy
9.5.1 Overview
9.5.2 Online Pharmacy: Antacid Market - Revenue and Forecast to 2027 (US$ Million)
10. Antacid Market Revenue and Forecasts to 2027 - Geographical Analysis
10.1 Asia-Pacific: Antacid Market
10.1.1 Overview
10.1.2 Asia-Pacific: Antacid Market, by Country, 2019 & 2027 (%)
10.1.3 China: Antacid Market, - Revenue and Forecast to 2027 (USD Million)
10.1.3.1 China: Antacid Market, - Revenue and Forecast to 2027 (USD Million)
10.1.3.2 China: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.3.3 China: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.3.3.1 China: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.3.4 China: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.4 Japan: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.1 Japan: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.4.2 Japan: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.4.3 Japan: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.4.3.1 Japan: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.4.4 Japan: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.5 India: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.1 India: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.5.2 India: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.5.3 India: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.5.4 India: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.5.5 India: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.6 South Korea: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.6.1 South Korea: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.6.2 South Korea: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.6.3 South Korea: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.6.3.1 South Korea: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.6.4 South Korea: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.7 Australia: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Australia: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Australia: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Australia: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.7.3.1 Australia: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Australia: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
10.1.8 Rest of Asia Pacific: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.1 Rest of Asia Pacific: Antacid Market - Revenue and Forecast to 2027 (USD Million)
10.1.8.2 Rest of Asia Pacific: Antacid Market, by Dosage Form - Revenue and Forecast to 2027 (USD Million)
10.1.8.3 Rest of Asia Pacific: Antacid Market, by Drug Class - Revenue and Forecast to 2027 (USD Million)
10.1.8.3.1 Rest of Asia Pacific: Antacid Market, by Acid Neutralizers - Revenue and Forecast to 2027 (USD Million)
10.1.8.4 Rest of Asia Pacific: Antacid Market, by Distribution Channel - Revenue and Forecast to 2027 (USD Million)
11. Impact Of COVID-19 Pandemic on Asia Pacific Antacid Market
11.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. COMPANY PROFILES
13.1 Bayer AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sun Pharmaceutical Industries Ltd
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sanofi
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Boehringer Ingelheim International GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Dr. Reddy's Laboratories
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Pfizer Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 roducts and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Reckitt Benckiser Group Plc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Procter & Gamble
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About the Publishers
14.2 Glossary of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories
  • Pfizer Inc
  • Reckitt Benckiser Group Plc
  • Procter & Gamble

Table Information